Inactivation of ABCC1 was sufficient to re-sensitize resistant leukemia cells to Venetoclax treatment and high ABCC1 expression predicted inferior responses to Venetoclax in AML patients. This evidence concerns the gene ABCC1 and acute myeloid leukemia.